Eupraxia Pharmaceuticals (EPRX) Total Liabilities (2022 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Total Liabilities of $9.2 million for Q1 2026, up 316.62% year-over-year from $2.2 million in Q1 2025, and up 60.69% quarter-over-quarter from $5.7 million in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Total Liabilities (2022 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Total Liabilities for 5 consecutive years, with $9.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 316.62% year-over-year to $9.2 million; the TTM figure through Mar 2026 stood at $9.2 million (up 316.62% YoY), while the FY2025 annual figure was $5.7 million, up 83.8% from the prior year.
- Total Liabilities grew to $9.2 million in Q1 2026 per EPRX's latest filing, from $5.7 million in the prior quarter.
- Across five years, Total Liabilities topped out at $19.4 million in Q4 2023 and bottomed at $2.2 million in Q1 2025.
- Historically, Total Liabilities has averaged $8.2 million across 5 years, with a median of $5.7 million in 2025.
- Annual changes were most pronounced in 2025 — Total Liabilities tumbled 88.13% — and 2026, when it soared 316.62%.
- Eupraxia Pharmaceuticals' Total Liabilities stood at $11.9 million in 2022, then surged by 62.61% to $19.4 million in 2023, then tumbled by 83.98% to $3.1 million in 2024, then jumped by 83.8% to $5.7 million in 2025, then soared by 60.69% to $9.2 million in 2026.
- Business Quant data shows EPRX's Total Liabilities at $9.2 million in Q1 2026, $5.7 million in Q4 2025, and $3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | 9.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.17 Mn |
| Dec 31, 2025 | 5.70 Mn |
| Sep 30, 2025 | 3.91 Mn |
| Jun 30, 2025 | 2.62 Mn |
| Mar 31, 2025 | 2.20 Mn |
| Dec 31, 2024 | 3.10 Mn |
| Sep 30, 2024 | 2.39 Mn |
| Jun 30, 2024 | 11.64 Mn |
| Mar 31, 2024 | 18.53 Mn |
| Dec 31, 2023 | 19.37 Mn |
| Dec 31, 2022 | 11.91 Mn |